Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

Next Previous
Search
Trial Profile

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary) ; Tislelizumab (Primary) ; Bevacizumab; Capecitabine; Fruquintinib; Ociperlimab; Pemetrexed; Sitravatinib; Temozolomide
  • Indications Cancer; Glioblastoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene

    • Most Recent Events

    • 13 May 2024 Planned End Date changed from 1 Aug 2024 to 1 Dec 2026.
    • 13 May 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2026.
    • 26 Jun 2023 The protocol of this study has been amended as new drugs has been added in this study, hence number of arms has changed to 11.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top